YL201 — Investigational Agent
Antibody-Drug Conjugate · Phase 1 · MediLink Therapeutics (Suzhou)
Mechanism of Action
B7-H3 (CD276)-directed antibody-drug conjugate delivering a topoisomerase I inhibitor payload via a proprietary tumor microenvironment-activated cleavable linker, producing targeted cytotoxicity and bystander killing in B7-H3-overexpressing tumors.
Investigational Indications
- Small cell lung cancer
- Non-small cell lung cancer
- B7-H3-expressing advanced solid tumors